The UK Association of Anaesthetists published comprehensive multidisciplinary consensus in January 2025, recommending that GLP-1 receptor agonists be continued before surgery with individualised risk assessment [42]
Changes in the gut microbiome, highly processed foods, chronic stress, not eating enough protein, weight gain, and poor digestion can all affect the gut cells that release GLP-1 the hormone that signals fullness, helps regulate blood sugar, and supports metabolism
Third, consider genetic testing to see if alternative compounds better match your metabolism
Manufacturers are investing heavily in expanding indications, developing higher-dose formulations, and advancing next-generation compounds
By seemingly targeting the growth hormone axis through their supposed distinct mechanisms of action, Tesamorelin and Ipamorelin may collectively stimulate the pituitary gland, thereby potentially enhancing the release of endogenous growth hormone